III. 7 Step-Down Phase

The step-down phase is not the withdrawal of treatment but its success: as external support tapers, the microbiome learns to sustain itself without reinforcement.

ℹSTEP-DOWN PHASE ENTRY CRITERIAThe step-down phase may only begin when all of the following conditions are met simultaneously:

• Stable symptom profile for ≥2 consecutive weeks
• Bristol Stool Scale consistently 3–4
• No new or worsening symptoms over the preceding 14 days
• Diary confirms adherence to the full consolidation dosing schedule

Step-Down Is Not Withdrawal – The Ecology of Decreasing External Support

The step-down phase is the third and final active phase of the MicroBiome Bank FMT protocol (a proprietary pilot protocol not independently validated by external RCT). Its defining feature is the gradual reduction of external microbial input – the progressive decrease in capsule dose frequency – while the now-consolidated donor community transitions toward autonomous self-maintenance. The step-down phase is not the end of treatment in the conventional sense; it is the beginning of the patient's microbiome functioning independently, without requiring continuous external reinforcement.

A common and clinically important misconception is that reducing capsule frequency means the treatment is being withdrawn, or that the patient is being left without support. The inverse is true: step-down is initiated precisely because the treatment has worked well enough that external support can be reduced. The ecological analogy is precise: a forest restoration project does not require indefinite replanting once the planted trees have established root systems, spread canopy, and begun self-seeding. The intervention succeeded; its continuation at the same intensity would be redundant and potentially counterproductive by preventing the emerging community from developing autonomous ecological dynamics [480], [108].

The biological rationale for step-down is equally grounded in immune physiology. Sustained high-frequency microbial dosing over extended periods may maintain a state of low-grade mucosal immune activation – the immune system continuously sampling incoming material – that is suboptimal for the long-term stabilization of a mucosal tolerogenic response. Reducing dose frequency allows the mucosal immune system to consolidate tolerance to the established community without the recurring stimulus of new high-density inocula [481], [482]. Step-down is therefore not just logistically convenient; it may actively support the immunological maturation that underlies durable remission.

The Step-Down Schedule – From Daily to Independence

The step-down schedule is individualized by the clinical team based on the patient's phase 2 response trajectory, underlying diagnosis, immune profile, and exposome factors. The general framework follows a decreasing frequency model over weeks 7–12 or longer, with clinical reassessment at each transition point. A typical step-down trajectory for a non-CDI patient who has completed 60 days of consolidation is illustrated below; individual schedules may be more conservative or more rapid depending on clinical assessment.

Table 9 – Typical step-down frequency schedule for non-CDI patients completing 60-day consolidation (MicroBiome Bank clinical protocol; external RCT validation ongoing) # Individual schedules are determined by the clinical team; transitions occur only when stability criteria are met at the current stage. Some patients with severe or refractory conditions may require extended maintenance at Stage 4 or 5 rather than progressing to autonomous maintenance.

Recognizing and Managing Rebound During Step-Down

Rebound – the recurrence or worsening of symptoms during a step-down stage – is the most important clinical signal to monitor during Phase 3. It indicates that the donor community's autonomous stability at the current dosing frequency is insufficient to maintain ecological equilibrium without additional external support. Rebound does not mean the FMT has failed; it means the step-down is proceeding faster than the community's current level of ecological independence supports.

Distinguishing rebound from normal fluctuation. Normal day-to-day symptom variation – small changes in stool consistency, mild bloating after dietary variation, transient fatigue – continues throughout step-down and is not rebound. Rebound is characterized by a directional, sustained trend: symptoms worsening progressively over 4–7 consecutive days following a frequency reduction, returning toward or beyond the pre-FMT baseline level, and not explained by an identifiable dietary or lifestyle trigger. The Food and Symptom Diary is the primary tool for distinguishing rebound from fluctuation: a trend is only interpretable with daily data across a full week.

Protocol response to rebound. If rebound is identified during step-down, the protocol response is stepback, not re-induction: the patient returns to the previous dosing frequency stage and stabilizes for a minimum of 4 weeks before attempting the same frequency reduction again. This stepback is not a failure; it is the protocol functioning correctly, preventing the ecological regression that would follow if the reduced frequency were maintained in the face of a clear rebound signal. In a minority of patients whose community does not achieve autonomous stability even at Stage 4 or 5 dosing after multiple stepback attempts, longer-term maintenance at low frequency may be indicated indefinitely. This is a clinical decision made in the context of the patient's diagnosis, quality of life, and overall treatment trajectory.

The role of lifestyle in preventing rebound. Rebound risk during step-down is directly modulated by the lifestyle environment the patient maintains. A patient reducing capsule frequency while simultaneously maintaining high dietary fiber intake, regular sleep, moderate physical activity, and low-stress conditions is providing optimal ecological conditions for community autonomy. A patient reducing capsule frequency while also deteriorating in diet, sleep, or stress management is compounding the reduction in external microbial support with a reduction in favorable host conditions – a combination that substantially elevates rebound risk [483]. The step-down phase is therefore not the time to relax lifestyle modifications; it is the time to demonstrate that those modifications are sustainable and robust enough to support the community without external reinforcement.

Durability of engraftment and long-term outcome. Strain-level tracking studies show that durable engraftment of donor strains is closely associated with the long-term clinical outcome of FMT [484]. There is as yet no uniform long-term randomized evidence for the independent effect of post-step-down lifestyle recommendations (sustained fiber intake, judicious avoidance of broad-spectrum antibiotics); on the ecological logic of engraftment, however, they can be presented as reasonable supportive recommendations for sustaining results.

Long-Term Maintenance – The Microbiome After FMT

The goal of the complete FMT protocol – compatibility assessment, induction, consolidation, and step-down – is a self-sustaining microbial ecosystem that no longer requires scheduled FMT to maintain its functional state. What does this ecosystem look like, and what does long-term maintenance actually entail for the patient?

What ‘autonomous’ means in ecological terms. Autonomous microbiome stability does not mean static or unchanging. A stable, resilient ecosystem is one that can absorb perturbations – dietary changes, transient illness, stress, occasional antibiotic exposure – and return to its characteristic functional state after each disturbance, rather than undergoing irreversible compositional shifts [480], [114]. The goal is not a fixed microbiome composition identical to the donor; it is a recipient microbiome that incorporates key donor-derived functional capabilities (colonization resistance, butyrate production, immune regulatory signaling) in a stable, host-integrated community. Individual recipients will develop different post-FMT compositions that nonetheless share these functional properties [156].

Long-term donor engraftment: what the evidence shows. Strain-level follow-up studies show that donor and recipient strains coexist durably after the procedure, and that the extent of engraftment is largely governed by the composition of the recipient's own community [108], [156], [488]. Clinical experience suggests that the proportional representation of donor taxa gradually declines over the following months as the recipient's own microbial signature reasserts itself – but no direct, strain-level measurement of that multi-year trajectory is available. This is expected and does not indicate treatment failure, provided the functional benefits (symptom remission, colonization resistance, SCFA production) are maintained. In some patients, specific donor keystone species show remarkable long-term persistence – detectable by strain-level metagenomic tracking even years after FMT – particularly those that occupied niches where the recipient had no equivalent endogenous taxa [484]. The clinical significance of these engraftment patterns is an active area of research [488].

When might further FMT be needed? A proportion of patients who achieve autonomous maintenance will experience clinically significant ecological regression – return of primary symptoms approaching pre-FMT severity – over a period of 12–24 months, particularly following major ecological perturbations: extended antibiotic courses, severe gastrointestinal illness, major surgery, or prolonged high-stress periods. These patients may be candidates for on-demand maintenance FMT – a single consolidation course rather than full re-induction – to re-establish ecological stability. The clinical team will discuss the criteria and logistics of on-demand maintenance at the final protocol review. Patients should not interpret long-term regression as meaning the original FMT was ineffective; the ecology changed, not the original intervention.

The Complete FMT Protocol – An Integrated Overview

Table 10 – Complete FMT protocol overview: all phases from compatibility assessment to autonomous maintenance # This table provides an integrated summary of the entire treatment journey described in Chapters II.1–II.7.

Life After FMT – Maintaining the Ecosystem You Have Built

The completion of the FMT protocol is not the end of the clinical relationship between the patient and the microbiome. It is the beginning of a different relationship: one in which the patient is no longer receiving external microbial support but is actively sustaining an internal ecosystem through their daily behavioral choices. The chapters that follow in this guide – covering dietary patterns, meal timing, sleep, physical activity, stress, and other lifestyle factors – are not addenda to the FMT protocol. They are its permanent infrastructure. Every fiber-containing meal, every consistent sleep schedule, every session of moderate exercise is an investment in the ecological stability of the community that the FMT built.

The link between long-term FMT success and lifestyle maintenance is mechanistically plausible but not yet supported by direct human evidence. What is established: donor strain persistence varies considerably between recipients, and durable donor–recipient strain coexistence can be maintained for months [488]; and sustained butyrate production depends directly on continued intake of fermentable fibre [483]. An ecological advantage can therefore be expected in patients who sustain high dietary diversity, regular physical activity and a low inflammatory burden – but no dedicated study has yet quantified the relationship between lifestyle and donor species persistence at 12–24 months. The FMT transferred the community. The patient's choices determine whether it stays.

Microbiota Effects

• Progressive reduction in capsule dosing frequency during step-down is associated with an increase in the ratio of recipient-derived to donor-derived taxa in stool microbiome sequencing, reflecting the gradual reassertion of host ecological conditions; this compositional shift is expected and clinically acceptable provided functional markers (SCFA production, colonization resistance, symptom stability) are maintained [108], [156].
• Ecological resilience – the community's ability to return to its characteristic composition following perturbation – increases through the step-down phase as metabolic redundancy deepens and mutualistic interspecies relationships mature; resilience is measurable as the speed and completeness of community recovery after a defined dietary or pharmacological challenge [480], [114].
• Donor strains and the recipient's own strains can coexist durably after FMT: in the patients followed by Li and colleagues, a proportion of donor strains remained stably detectable in the months after the procedure, primarily those that filled vacant ecological niches in the recipient's pre-FMT community [488]. Beyond this, there are still not enough published follow-up data on the longer-term course of donor species abundance – including the rate of persistence at 12–24 months.
• Butyrate production capacity – the primary functional metric of consolidation success – shows greater long-term stability than species-level composition: recipients who maintain high dietary fiber intake preserve elevated fecal butyrate concentrations even as donor species representation decreases, indicating that the functional capacity has been transferred to the broader resident community rather than depending solely on persistent donor taxa [483].
• Secondary bile acid metabolism, which FMT restores, is one of the key mechanisms of protection against CDI recurrence: the bile salt hydrolase and 7α-dehydroxylating activity of the transferred community re-establishes the secondary bile acid profile that inhibits C. difficile spore germination [487]. The restored community remains within the healthy range in the months following treatment without continued FMT dosing [048]; there are, however, no published patient data on the durability of secondary bile acid concentrations beyond 12 months.
• The development of mucosal immune tolerance is mechanistically well supported: short-chain fatty acids produced by commensal bacteria – primarily butyrate – drive the differentiation of peripheral and colonic regulatory T cells (Treg) in mice, through epigenetic modification of the Foxp3 locus [481], [482]. There is, however, no human FMT follow-up showing that immune maturation at 6 months is a better predictor of ecological stability at 24 months than species-level engraftment metrics – this remains a working hypothesis.
• Circadian microbiome rhythmicity – the diurnal oscillation of microbial community composition synchronized with host feeding and sleep – is restored progressively through consolidation and maintained through step-down in patients with consistent sleep and meal timing; loss of circadian lifestyle regularity in the maintenance phase is associated with progressive dampening of these oscillations and increased vulnerability to ecological destabilization [021].

Patient Guidance

• Understand the step-down phase as a positive clinical signal, not a reduction in support. Your clinical team initiates step-down because the evidence from your diary and clinical assessment indicates your microbiome community has reached sufficient stability to begin functioning with less external reinforcement. It is a marker of progress.
• Follow the step-down schedule your clinical team provides without adjusting it independently. Do not skip stages to accelerate the process, and do not extend stages beyond the scheduled duration without clinical guidance. The schedule is calibrated to your individual trajectory; deviations in either direction increase the risk of either rebound or unnecessarily prolonged treatment.
• Keep your Food and Symptom Diary throughout the step-down phase, shifting to a weekly summary format from Stage 3 onward unless instructed otherwise. Record your key metrics on the same days each week to allow trend comparison. The diary remains the primary monitoring tool even as clinical contacts become less frequent.
• During each stage transition – particularly the first reduction from 5 to 3 days per week – increase your attention to early rebound signals for the first 7–10 days. If you notice a directional worsening trend in stool consistency, energy, or your underlying condition symptoms over 4–7 consecutive days, contact your clinical team before the next scheduled review. Early identification of rebound allows stepback before significant ecological regression occurs.
• Maintain or strengthen your lifestyle foundation during step-down. This is the phase in which the community must prove it can sustain itself – your dietary fiber intake, sleep consistency, physical activity, and stress management are the ecological infrastructure it relies on. Reducing both capsule frequency and lifestyle quality simultaneously is the most common pattern that leads to rebound.
• If you reach autonomous maintenance and later experience a period of significant ecological regression – return of primary symptoms over weeks or months – contact your clinical team before attempting any self-management strategy. Do not restart probiotics, restrictive diets, or over-the-counter gut supplements independently. A clinical assessment can determine whether on-demand maintenance FMT, dietary intervention, or other measures are appropriate.
• After completing the full protocol, attend the annual clinical review recommended by your team even if you feel well. Long-term microbiome monitoring allows early detection of compositional drift before it produces symptomatic regression, and enables proactive intervention before full rebound occurs.
• Inform any new physician or specialist you see – including dentists, surgeons, and emergency practitioners – that you have undergone FMT treatment. This is relevant for antibiotic prescribing decisions, bowel preparation requirements for any future procedures, and assessment of any gastrointestinal symptoms that may arise. Carry a brief written summary of your FMT treatment dates, delivery route, and clinical team contact details for this purpose.
• Think of the dietary, sleep, and physical activity recommendations in the remaining chapters of this guide not as optional lifestyle advice but as the daily maintenance protocol for the ecosystem you have built. The FMT was the ecological intervention; the rest of the guide describes how to maintain the conditions in which that intervention can produce permanent benefit.
• If you have questions about the long-term trajectory of your treatment, ask your clinical team at your next review for a copy of your microbiome assessment data if available, and a discussion of what the data shows about your community's current functional state. Understanding your own data is an active part of long-term engagement with your health, not a passive receipt of clinical decisions made about you.

Evidence by Indication: A Summary

The following table summarises the current strength of evidence for FMT across the primary indications discussed in this guide. Evidence ratings reflect the quality, consistency, and quantity of available clinical trials and systematic reviews at time of writing.

Table 11 – FMT clinical indication evidence summary # Evidence levels, primary evidence base, and clinical notes for each supported indication at time of writing.

Note: Evidence ratings are provided to support informed patient decision-making. They do not constitute clinical recommendations. Discuss your specific indication and evidence base with your treating physician.

References

[021] Thaiss CA, Zeevi D, Levy M, Zilberman-Schapira G, Elinav E et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell. 2014. Link

The composition and function of the gut microbiota follow a daily rhythm: bacterial abundance and metabolic activity oscillate across the light-dark cycle, and this oscillation is driven chiefly by the host's feeding rhythm. When the rhythm is disrupted — modelled here in mice and in human samples after intercontinental flight — microbiota oscillation is abolished and dysbiosis develops; transferring the arrhythmic flora into germ-free mice induces metabolic disturbance. Conclusion: a regular daily rhythm is one precondition of microbiota stability — hence the value of a fixed wake time and morning light from the first days of treatment.

[048] Weingarden A, González A, Vázquez-Baeza Y, Weiss S, Humphry G, Berg-Lyons D, Knights D, Unno T, Bobr A, Kang J, Khoruts A, Knight R, Sadowsky MJ. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium. difficile infection. Microbiome. 2015. Link

Longitudinal microbiome characterisation following FMT in four patients with recurrent CDI, sampling daily for 28 days and weekly to 84 days post-treatment, over a total of 151 days. The recipient microbiota rapidly normalised from a markedly dysbiotic state to a healthy-range composition within days. Composition continued to change thereafter, diverging from the original donor implant material and fluctuating dynamically over both the short and the long term – while remaining throughout within the cloud of healthy microbiota. The paper supports the framing in this Guide that successful MTT produces a self-sustaining recipient ecology, not a permanent donor-tracked imprint.

[108] Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, Allegretti JR, Smith MB, Xavier RJ, Alm EJ. Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018. Link

Strain-level tracking after FMT: the authors examined what determines whether a given donor strain engrafts in the recipient. The strongest predictor is the **composition of the recipient's own community** — a strain engrafts when a relative is already present, or when a free ecological niche exists; donor strain richness and strain abundance also matter. Engraftment therefore follows ecological rules rather than chance, and is modifiable from the recipient's side. Important: the paper describes strain-level determinants; it does not prove fibre availability as a modifiable factor in an RCT.

[114] Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012. Link

Review of the diversity, stability and resilience of the human gut microbiota. Applying ecological concepts to the gut, the authors argue that **species richness and evenness** are key indicators of a community's capacity to withstand perturbation: functional redundancy in a diverse community means the loss of a single taxon is less disruptive. They discuss the concept of dysbiosis and the association of low-diversity states with several diseases. Important: a **review** providing an ecological framework; it does not treat CDI separately and offers no causal evidence.

[156] Ianiro G, Puncochar M, Karcher N, Porcari S, Armanini F, Asnicar F, Segata N. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat Med. 2022. Link

Integrated shotgun-metagenomic meta-analysis of 226 triads (donor, pre-FMT and post-FMT recipient) across eight different disease types, using improved strain profiling. The key finding: **recipients with higher donor-strain engraftment were more likely to achieve clinical success** after FMT (P=0.017). Engraftment depends on the donor, the delivery route (multi-route — e.g. capsule plus colonoscopy together — gives higher engraftment) and the recipient (higher in antibiotic-treated infectious-disease recipients than in antibiotic-naive noncommunicable-disease patients); Bacteroidetes and Actinobacteria species engraft better. This entry is the source for the IV.3 claim that, because of donor-dependent engraftment variability, an alternative donor lot (LOT switch) can improve the outcome. **LIMITATION:** an observational meta-analysis across eight disease types (not CDI alone), measuring association; it did not study product-LOT switching as such.

[480] Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight R. Bacterial community variation in human body habitats across space and time. Science. 2009. Link

Spatial-temporal survey of the human microbiota sampling up to 27 body sites in 7–9 healthy adults on four occasions. Community composition was determined primarily by body habitat; within habitats, interpersonal variability was high while temporal variability within individuals was minimal. Skin locations harboured more diverse communities than gut and mouth and differed in community assembly patterns. The data establish baseline healthy biogeography of the human microbiota and a reference for disease-associated deviations.

[481] Arpaia N, Campbell C, Fan X et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013. Link

Mechanistic study showing that microbial metabolic by-products are sensed by host cells and modulate intestinal regulatory T cell (Treg) generation. The work links commensal microbial metabolism to gut immune homeostasis through Foxp3+ Treg cells, identifying microbial cues as drivers of anti-inflammatory T-cell differentiation. Findings establish a molecular bridge between diet, microbial metabolism, and mucosal immune regulation, supporting microbiome-targeted strategies for inflammatory disease.

[482] Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013. Link

Mechanistic study in mice showing that the SCFA butyrate, produced by Clostridia fermentation of dietary fibre, induces differentiation of colonic regulatory T (Treg) cells. NMR-based metabolomics showed luminal SCFA concentrations positively correlated with colonic Treg numbers. Butyrate acted via histone deacetylase inhibition on Foxp3 locus regulation. Identifies butyrate as a microbial mediator of mucosal immune tolerance and supports butyrate-augmenting interventions in inflammatory bowel disease.

[483] Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Martens EC, Schloss PD. Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. mBio. 2019. Link

Two-week dietary intervention in 174 healthy young adults supplementing with resistant starch from potatoes (RPS), resistant starch from maize (RMS), inulin, or accessible corn-starch control. RPS produced the greatest increase in total SCFAs including butyrate. Most microbiomes responded to RPS with increased bifidobacteria, but responders with rising Ruminococcus bromii or Clostridium chartatabidum showed the highest butyrate concentrations. The study demonstrates substrate- and taxon-specific routes to butyrate enrichment, informing personalized prebiotic strategies.

[484] Aggarwala, V., Mogno, I., Li, Z., et al. Precise quantification of bacterial strains after fecal microbiota transplantation delineates long-term engraftment and explains outcomes. Nature Microbiology. 2021. Link

The authors built a strain-level tracking framework (Strainer) for shotgun metagenomics and, across 13 longitudinal FMT interventions, detected stable engraftment of ~71% of donor strains up to 5 years post-FMT. The degree of donor-strain engraftment independently explained clinical outcome (relapse vs. success) with 100% precision and 95% recall.

[487] Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol. 2016. Link

Mechanistic review of FMT in recurrent C. difficile infection summarizing the proposed mechanisms of action: direct competition between C. difficile and commensals introduced by FMT, restoration of secondary bile acid metabolism (which inhibits C. difficile germination), and repair of the gut barrier through mucosal immune stimulation. The review consolidates the mechanistic basis for FMT in CDI and highlights translational implications for engineered microbial therapeutics targeting these pathways.

[488] Li SS, Zhu A, Benes V et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science. 2016. Link

Strain-level monitoring study using single-nucleotide variants in metagenomes from a metabolic-syndrome FMT trial to quantify donor microbial engraftment. Extensive coexistence of donor and recipient strains was observed and persisted for 3 months post-FMT. Conspecific strain colonization succeeded more often than new-species introduction, the latter remaining within healthy-individual fluctuation levels. Same-donor recipients showed correlated colonization patterns. The data refine our understanding of strain dynamics after FMT in metabolic disease.